Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an antibody-drug conjugate.
The deal includes an upfront fee of €160 million ($169 million) and could swell to €1.4 billion if development, regulatory and commercial objectives are met, making it one of the largest pipeline-boosting in-licensing deals for the German company in recent years.
